Dec 30, 2021 7:00 am EST Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
Nov 05, 2021 7:30 am EDT Immunovant Reports Financial Results for the Quarter Ended September 30, 2021